Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kim Ross

Dermatology La Vernia, TX Medical Doctor

NPI 1184600165 CMS profile 7989

309 Silverado, La Vernia, TX 78121

Open in the dashboard

General payments

$55,738

556 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kim Ross of La Vernia, TX is reported in the CMS Open Payments database as having received $55,738 across 556 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $23,364 136
2024 General $10,811 101
2023 General $12,505 79
2022 General $3,061 62
2021 General $2,085 54
2020 General $931 48
2019 General $2,981 76

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kim Ross
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Kim Ross were reported at $23,364. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Kim Ross Dermatology median Middle half National median
2019 $2,981 $454 $129–$1,240 $163
2020 $931 $235 $81–$756 $114
2021 $2,085 $377 $108–$1,108 $132
2022 $3,061 $514 $143–$1,391 $149
2023 $12,505 $607 $159–$1,674 $160
2024 $10,811 $751 $204–$1,903 $164
2025 $23,364 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $27,720 44 payments
  2. E.R. Squibb & Sons, L.L.C. $12,137 59 payments
  3. Merz North America, Inc. $4,734 18 payments
  4. Galderma Laboratories, L.P. $1,191 45 payments
  5. AbbVie, Inc. $1,071 39 payments
  6. Lilly USA, LLC $871 33 payments
  7. Janssen Biotech, Inc. $855 32 payments
  8. UCB, Inc. $824 24 payments
  9. Ortho Dermatologics, a division of Bausch Health US, LLC $605 14 payments
  10. Allergan Inc. $576 37 payments
  11. Other $5,153 211 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $26,020 11 payments
  2. Food and Beverage $17,109 528 payments
  3. Consulting Fee $9,905 6 payments
  4. Travel and Lodging $1,812 3 payments
  5. Honoraria $500 1 payment
  6. Education $392 7 payments
Products named General payments · program years 2019–2025
  1. Otezla $27,612 39 payments
  2. Xeomin $3,461 14 payments
  3. SOTYKTU $1,211 47 payments
  4. TREMFYA $798 29 payments
  5. Bimzelx $683 17 payments
  6. TALTZ $647 31 payments
  7. Minolira 105mg $540 3 payments
  8. Rhofade $540 3 payments
  9. Minolira 135mg $540 3 payments
  10. CLODERM $540 3 payments
  11. Other $11,486 454 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,193

Median for Dermatology: 534

Drug cost

$853,537

Median for Dermatology: $67,151

Branded share of claims

16.7%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 92 $363,825
Otezla Apremilast Brand 41 $206,101
Humira(Cf) Pen Adalimumab Brand 22 $145,803
Sotyktu Deucravacitinib Brand 13 $110,425
Clobetasol Propionate Generic 139 $7,175
Pimecrolimus Generic 32 $5,680
Imiquimod Generic 165 $4,450
Fluocinonide Generic 56 $1,884
Triamcinolone Acetonide Generic 118 $1,709
Doxycycline Hyclate Generic 94 $1,503

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 102 billing codes

Paid by Medicare

$1,320,930

Of which drugs: $72,489

Medicare patients

1,486

Average age 74

Services billed

75,012

836 women, 650 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 43%
Diabetes 29%
Ischemic heart disease 24%
Chronic kidney disease 23%
Depression 16%
Atrial fibrillation 15%
Osteoporosis 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 170 53,800 $71,656
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 79 232 $171

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Otezla
  • Amgen Inc. $8,085
$8,085 41 —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $729
$729 13 —
TREMFYA
  • Janssen Biotech, Inc. $242
$242 — —
CIBINQO
  • PFIZER INC. $144
$144 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $82
  • GENZYME CORPORATION $45
$128 92 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

556 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record